Summary
The systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade produced by labetalol were assessed in 24 normotensive patients with angina pectoris and an ischemic electrocardiographic response to exercise stress. Both the intravenous (0.5 mg/kg) and oral (200 mg) formulations of labetalol were evaluated. At rest, labetalol produced systemic vasodilation (systemic vascular resistance-16% after intravenous and-8% after oral labetalol, both p<0.05) without change in heart rate. Aortic pressure usually was lower and cardiac output preserved or increased. Left ventricular end-diastolic pressure was unchanged. Coronary sinus flow was usually unchanged after either route of administration. Exercise duration was prolonged in 14 of the 20 patients with severe coronary artery disease. During exercise, tachycardia was blunted (-12% after intravenous,-7% after oral labetalol, both p<0.05) as was the increase in mean aortic pressure (-12% and-13% intravenous and oral labetalol respectively, both p<0.05), left ventricular end-diastolic pressure [-7% and-1%, respectively, both p=not significant (NS)] was unchanged. Coronary sinus flow (-16% and-25%, respectively, both p<0.05) was decreased as heart rate and aortic pressure were lower. Cardiac output, systemic vascular resistance, and coronary vascular resistance were similar to control exercise. The hemodynamic effects of intravenous and oral labetalol are, in general, similar. Hemodynamic responses differ from those produced by other beta-blockers and by calcium antagonists.
Similar content being viewed by others
References
Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (Labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 1987; 59:1084–1088.
Feldman RL, Prida XE, Hill JA. Systemic and coronary hemodynamic effects of combined oral alpha and beta adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests. Clin Cardiol (in press).
Mehta J, Feldman RL, Marx JD, et al. Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects. Am J Med 1983; 75:32–39.
Gagnon RM, Morissette M, Presant S, et al. Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J Cardiol 1982; 49:1267–1269.
Silke B, Nelson GIC, Ahuja RC et al. Comparative hemodynamic dose response effects of propranolol and labetalol in coronary heart disease. Br Heart J 1982; 48:364–371.
Koch G. Differential hemodynamic effects of β-adrenoceptor blockers, Ca antagonists and combined α-β-receptor blockade in ischemic heart disease. Acta Med Scand 1986; 219:17–22.
Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol 1981; 48:917–928.
Quyyumi AA, Wright C, Mockus L, et al. Effects of combined alpha and bets adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. Br Heart J 1985; 53:47–52.
Upward JW, Akhras F, Jackson G. Oral labetalol in the management of stable angina pectoris in normotensive patients. Br Heart J 1985; 53:53–57.
Prida XE, Feldman RL, Hill JA, et al. Comparison of selective (β1) and nonselective (beta 1 and beta 2) beta-adrenergic blockade n systemic and coronary hemodynamic findings in angina pectoris. Am J Cardiol 1987; 60:244–248.
Lambert CR, Hill JA, Feldman RL, et al. Effects of nicardipine on exercise and pacing induced myocardial ischemia. Am J Cardiol 1987; 60:471–476.
Pepine CJ, Mehta J, Webster WW, et al. In vivo validation of thermodilution method to determine regional left ventricular blood flow in patients with coronary disease. Circulation 1978; 58:795–802.
Joyal M, Cremer K, Pieper J, et al. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol 1985; 56:413–417.
Joyal M, Cremer K, Pieper J, et al. Effects of diltiazem during tachycardia-induced angina pectoris. Am J Cardiol 1986; 57:10–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feldman, R.L., Prida, X.E., Lambert, C.R. et al. Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease. Cardiovasc Drug Ther 2, 355–361 (1988). https://doi.org/10.1007/BF00054643
Issue Date:
DOI: https://doi.org/10.1007/BF00054643